Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
TERUMO CORPORATION ADR Aktie jetzt für 0€ handeln | |||||
16.04. | Terumo Blood and Cell Technologies Names Patrick Daly as Chief Business Officer | 167 | PR Newswire | Daly, a 30-year veteran of the healthcare industry, is the latest leadership addition to help Terumo BCT unite business areas and fuel enterprise growth
LAKEWOOD... ► Artikel lesen | |
16.04. | Terumo Health Outcomes Now Offers FDA-Cleared Medis QFR 3.0 Software for Coronary Physiology Assessment in the US | 321 | PR Newswire | - Innovative AI software supports hospital adoption of advanced tools to improve cath lab workflow and patient comfort -
SOMERSET, N.J., April 16, 2025 /PRNewswire/... ► Artikel lesen | |
15.04. | Terumo Neuro wins FDA nod for first dual-layer carotid stent | 3 | MassDevice | ||
15.04. | Terumo Neuro Receives FDA Approval for Carotid Stent System | 161 | PR Newswire | First Dual-Layer Micromesh Carotid Stent Approved for Use in the U.S.
ALISO VIEJO, Calif., April 15, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular... ► Artikel lesen | |
19.03. | Terumo Neuro Celebrates 15 Years of the WEB Device: A Game-Changing Innovation in Aneurysm Treatment | 645 | PR Newswire | More than 25,000 Devices Implanted Worldwide from 2010-20251
ALISO VIEJO, Calif., March 19, 2025 /PRNewswire/ -- Terumo Neuro, a global leader in neurovascular innovation and a wholly... ► Artikel lesen | |
27.02. | Terumo and Daiichi Sankyo partner to support cardiovascular care in Vietnam | 9 | VnExpress | ||
13.02. | Terumo GAAP EPS of ¥66.51, revenue of ¥772.2B | 6 | Seeking Alpha | ||
14.01. | Terumo BCT, FUJIFILM Irvine Scientific Partner on T Cell Expansion Solution | 2 | Contract Pharma | ||
10.12.24 | Terumo, Medis announce strategic partnership to enhance cardiovascular care | 5 | MassDevice | ||
04.12.24 | Terumo launches R2P NaviCross peripheral support catheter in US | 6 | MassDevice | ||
16.10.24 | NAMSA und TERUMO kündigen strategische Outsourcing-Partnerschaft an | 408 | Business Wire | Die klinischen Forschungs-, Test- und Beratungsdienste von NAMSA werden dazu beitragen, die behördliche Zulassung des Medizinprodukteportfolios von TERUMO auf globaler Ebene zu beschleunigen. NAMSA... ► Artikel lesen | |
15.10.24 | NAMSA and TERUMO Announce Strategic Outsourcing Partnership | 622 | Business Wire | NAMSA's clinical research, testing and consulting services will help accelerate the regulatory approval of TERUMO's medical device portfolio on a global level. NAMSA, a world-leading MedTech... ► Artikel lesen | |
13.09.24 | MicroVention firmiert in Terumo Neuro um - Ausdruck eines erweiterten Fokus und strategischen Wachstums | 549 | Business Wire | MicroVention, Inc., ein weltweit führendes Unternehmen im Bereich neurovaskulärer Innovationen und eine hundertprozentige Tochtergesellschaft der Terumo Corporation, gab heute die offizielle Umbenennung... ► Artikel lesen | |
12.09.24 | MicroVention Rebrands to Terumo Neuro - Reflects Expanded Focus and Strategic Growth | 561 | Business Wire | MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately.... ► Artikel lesen | |
21.08.24 | Terumo-Aktie leicht im Plus (17,05 €) | 520 | ARIVA.de | Die Aktie von Terumo notiert am Mittwoch fester. Das Wertpapier kostete zuletzt 17,05 Euro. Das Wertpapier von Terumo verzeichnet aktuell einen Preisanstieg von 4,92 Prozent. Es hat sich um 80 Cent... ► Artikel lesen | |
06.08.24 | Guter Tag für Terumo-Aktionäre: Aktienkurs steigt deutlich (15,15 €) | 527 | ARIVA.de | Zu den großen Gewinnern an der Börse zählt heute das Wertpapier von Terumo . Der Kurs des Anteilsscheins legt kräftig zu. Die Aktie von Terumo gehört heute mit einem Kursplus von 5,94 Prozent zu den... ► Artikel lesen | |
06.08.24 | Terumo Corporation: Terumo Establishes Corporate Venture Capital "Terumo Ventures" | 490 | PR Newswire | TOKYO, Aug. 6, 2024 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced that it has established "Terumo Ventures," a Corporate Venture Capital (CVC) organization responsible for... ► Artikel lesen | |
28.05.24 | Terumo Cardiovascular Announces 510(K) Clearance for the CDI OneView Monitoring System | 337 | PR Newswire | All-new modular, expandable design displays up to 22 vital patient parameters with real-time convenience ANN ARBOR, Mich., May 28, 2024 /PRNewswire/ -- Terumo Cardiovascular, a global leader in... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDTRONIC | 77,16 | +4,07 % | Medtronic: Reading Your Brain Waves To Treat a Debilitating Disease | FDA approves Medtronic adaptive deep brain stimulation system for Parkinson's Disease NORTHAMPTON, MA / ACCESS Newswire / May 6, 2025 / Liza Bobrow didn't think it was a big deal when her handwriting... ► Artikel lesen | |
HCA HEALTHCARE | 326,70 | +3,95 % | Kurs von HCA fällt ab (287,6415 €) | Das Wertpapier von HCA notiert am Freitag ein wenig leichter. Die Aktie kostete zuletzt 326,87 US-Dollar. Ein Verlust von 4,26 Prozent steht gegenwärtig für die Aktie von HCA zu Buche. Das Wertpapier... ► Artikel lesen | |
LANTHEUS | 72,76 | +0,11 % | Lantheus Holdings, Inc.: Lantheus Announces Sale of SPECT Business to SHINE Technologies | Enables Lantheus to focus on innovative radiopharmaceuticals, while maximizing the value of its SPECT business SHINE will acquire products TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®... ► Artikel lesen | |
AMEDISYS | 85,00 | 0,00 % | Amedisys Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
ENVISTA | 16,700 | +6,37 % | NVST Stock Up on Q1 Earnings and Revenue Beat, Margins Crash | ||
CAREDX | 13,900 | 0,00 % | Analyst Expectations For CareDx's Future | ||
SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Third Quarter 2025 Results | Reports 23 Percent Increase in ARR to $20.4 Million and 43 Net New Platform Deployments, Positive Net Income and Record Adjusted EBITDA and Cashflow
HENDERSON... ► Artikel lesen | |
GT BIOPHARMA | 2,300 | 0,00 % | GT Biopharma, Inc. - 8-K, Current Report | ||
CARMAT | 0,811 | +2,66 % | CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson Implants, While Awaiting Potential Reimbursement of the Device in France | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
CHEMOMETEC | 67,40 | +2,51 % | Chemometec A/S: Continued growth in revenue and operating profit | Trading statement for Q3 2024/25 (1 January - 31 March 2025) Continued growth in revenue and operating profit Revenue was up by 26% in the third quarter of 2024/25 to DKK 124.2 million from DKK 98.9... ► Artikel lesen | |
HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
POLAREAN IMAGING | 0,001 | 0,00 % | Polarean Imaging PLC - Final Results | ||
PROMIMIC | 2,050 | -6,82 % | Curiteva & Promimic - Bonded by Innovation | HUNTSVILLE, ALABAMA / ACCESS Newswire / May 6, 2025 / Curiteva, a leader in 3D-printed Trabecular PEEK implant technology, is pleased to announce an expanded partnership with Promimic, pioneers in nanotechnology... ► Artikel lesen | |
ARRAIL GROUP | 0,204 | +6,25 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
DEVYSER DIAGNOSTICS | 10,660 | +2,70 % | Devyser Diagnostics AB: Devyser Diagnostics AB publishes quarterly report for the period January to March 2025 | "A quarter has passed since I took over as acting CEO and it has been an eventful first few months. Despite the turbulent environment, marked by geopolitical uncertainty, we are able to report our second... ► Artikel lesen |